Stephane Borentain

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 5

Top Topics

Randomized Controlled Trial

Top Venues

Neuropsychiatric disease and treatment

Journal of psychopharmacology (Oxford, England)

International journal of methods in psychiatric research

This page only lists publications with an associated author ORCID identifier.

Publications

Stephane Borentain, Jagadish Gogate, David Williamson, Thomas Carmody, Madhukar H Trivedi, Carol Jamieson, Patricia Cabrera, Vanina Popova, Ewa Wajs, Allitia DiBernardo, Ella J Daly
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. International journal of methods in psychiatric research 31 (4) (2022)
Joachim Morrens, Maju Mathews, Vanina Popova, Stephane Borentain, Benoit Rive, Beatriz Gonzalez Martin Moro, Carol Jamieson, Qiaoyi Zhang
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression. Neuropsychiatric disease and treatment 18 (2022)
Stephane Borentain, Pooja Desai, Dong-Jing Fu, Li Nancy Chen, Rosanne Lane, Maju Mathews, Carla M Canuso
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder". Journal of psychopharmacology (Oxford, England) (2022)
Bettina Diekamp, Stephane Borentain, Dong-Jing Fu, Robert Murray, Kristin Heerlein, Qiaoyi Zhang, Cornelius Schüle, Maju Mathews
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials. Neuropsychiatric disease and treatment 17 (2021)
Stephane Borentain, David Williamson, Ibrahim Turkoz, Vanina Popova, William V McCall, Maju Mathews, Frank Wiegand
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials. Neuropsychiatric disease and treatment 17 (2021)